BPC-157 vs TB-500: Structure, Pathways and Evidence

Q: What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-residue fragment of a gastric protein linked in studies to VEGFR2 and nitric oxide signalling. TB-500 is a 7-residue acetylated fragment (LKKTETQ) of thymosin beta-4's actin-binding site, linked to actin dynamics and cell migration. They are unrelated in sequence and origin.

Q: Which has more published research, BPC-157 or TB-500?

BPC-157 has a large body of animal research and a formal pharmacokinetic study. For TB-500, most biological research was done with full-length thymosin beta-4; studies of the heptapeptide itself are mainly analytical.

Q: Why are BPC-157 and TB-500 combined in blends?

Researchers interested in tissue repair models study them together because they are associated with different processes, angiogenesis for BPC-157 and actin-driven cell migration for thymosin beta-4. We are not aware of peer-reviewed studies testing the combination.

Q: Can BPC-157 and TB-500 be in the same vial?

Yes, they are supplied as a premixed blend. Both are water-soluble, and they have very different masses, so each can be identified separately by HPLC and mass spectrometry.

Q: Is either peptide approved for human use?

No. Neither BPC-157 nor TB-500 is an approved medicine in the US or EU.

BPC-157 and TB-500 are often mentioned together in tissue-repair research, but chemically they have nothing in common. BPC-157 is a 15-residue fragment of a gastric protein that studies associate with VEGFR2 and nitric oxide signalling. TB-500 is a 7-residue acetylated fragment of thymosin beta-4’s actin-binding site, associated with actin dynamics and cell migration. Their evidence bases also differ in kind, not just in size.

For laboratory research use only. The compounds discussed are not approved for human or veterinary use and are not drugs, foods or cosmetics. This article summarises published research and is not medical advice.

Key points

Different origins: gastric protein fragment vs thymosin beta-4 fragment.
Different size: 15 residues (1419.5 g/mol) vs 7 residues (~889 g/mol acetylated).
Different pathways: VEGFR2–Akt–eNOS for BPC-157; G-actin binding and migration for the Tβ4 region.
BPC-157 has direct animal and pharmacokinetic data; TB-500 biology is largely inferred from full-length Tβ4.
Neither is approved for human use.

Side-by-side comparison

	BPC-157	TB-500
Sequence	GEPPPGKPADDAGLV	Ac-LKKTETQ
Length / mass	15 aa / 1419.5 g/mol	7 aa / ~889 g/mol
Parent molecule	Protein described in human gastric juice	Thymosin beta-4 (43 aa), residues 17-23
Charge character	Acidic (2 Asp, 1 Glu vs 1 Lys)	Basic (2 Lys vs 1 Glu)
Main pathways studied	VEGFR2–Akt–eNOS; GH receptor; FAK–paxillin	G-actin sequestration region; migration, angiogenesis
Pharmacokinetics	t_1/2 <30 min in rats and dogs	No formal PK study of the heptapeptide found
Human data	3 small pilot studies (n = 30), very low certainty	None for TB-500; clinical trials exist for full-length Tβ4

Both compounds are available for laboratory research: BPC-157 and TB-500, each with lot-level HPLC and MS data.

How BPC-157 has been studied

BPC-157 research is built on direct experiments with the peptide. In human vascular endothelial cells and a rat ischemic hind-limb model, it increased VEGFR2 (but not VEGF-A) expression, promoted VEGFR2 internalisation, and activated the VEGFR2–Akt–eNOS pathway (Hsieh et al., 2017). In rat tendon fibroblasts it accelerated explant outgrowth, migration and spreading and improved survival under oxidative stress, without directly increasing proliferation (Chang et al., 2011). Its pharmacokinetics have been measured formally: the intact peptide has a plasma half-life under 30 minutes in rats and dogs (He et al., 2022). See what is BPC-157? for the full profile.

How TB-500 has been studied

TB-500’s scientific rationale comes from work on thymosin beta-4. Sosne and colleagues mapped Tβ4 activities to short sequences and linked the central actin-binding region, LKKTETQ, to angiogenesis, wound-repair processes and cell migration (Sosne et al., 2010). Full-length Tβ4 has progressed to clinical trials in areas such as eye and skin injury (Goldstein et al., 2015). The heptapeptide itself appears in the literature mainly through analytical work: Ho and colleagues identified N-acetylated LKKTETQ as the key ingredient of a commercial TB-500 product and developed an LC-MS method for it and its metabolites (Ho et al., 2012). The TB-500 profile explains the TB-500 vs Tβ4 distinction in more detail.

Strength of evidence compared

Evidence type	BPC-157	TB-500 (heptapeptide)
Mechanistic cell studies	Several, independent groups	Via Tβ4 active-site mapping
Animal injury models	Many	Mostly full-length Tβ4
Pharmacokinetics	Formal two-species study	Metabolite identification (doping control)
Human studies	Very low certainty (Poolton et al., 2026)	None identified

Combined in one vial

Because they are associated with different processes, the two peptides are frequently supplied together as a 1:1 blend for tissue-repair research. We are not aware of peer-reviewed studies that tested the combination. From an analytical point of view, a blend is straightforward to verify: the two components differ by about 530 Da and have opposite charge character, so they separate well by reverse-phase HPLC and are easily distinguished by MS. See the BPC-157 + TB-500 blend.

Handling

Both are lyophilized, water-soluble peptides. Store powder at −20 °C and solutions at 2–8 °C, avoid repeated freeze–thaw, and reconstitute as described in how to reconstitute peptides. Use the peptide reconstitution calculator for concentrations.

Related research

BPC-157 half-life
GLOW blend
TB-500 half-life

Frequently asked questions

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-residue fragment of a gastric protein linked in studies to VEGFR2 and nitric oxide signalling. TB-500 is a 7-residue acetylated fragment (LKKTETQ) of thymosin beta-4’s actin-binding site, linked to actin dynamics and cell migration. They are unrelated in sequence and origin.

Which has more published research, BPC-157 or TB-500?